CFH Human Pre-designed siRNA Set A

Cat. No.: C1461378

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

CFH Human Pre-designed siRNA Set A contains three designed siRNAs for CFH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CFH siRNA-1: 5 nmol (HPLC) CFH siRNA-2: 5 nmol (HPLC) CFH siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Product Line

biological_products

Application Protocols

Item-specific (from Product Data)

• Manufacturer‑validated applications, recommended cell lines, transfection reagents, working concentrations, and expected knockdown metrics: Not specified for this item; refer to CoA/Spec Sheet.

Where to look next

• Consult the CoA/Spec Sheet or contact technical support for item‑specific protocol recommendations.

Reminder

• Use appropriate negative/positive controls and verify knockdown at both transcript and protein levels for CFH.

Biological Roles

Item-specific (from Product Data)

• Target: Human CFH (Complement factor H). Additional biological details are not provided in the Product Data.

Biochemical function of CFH (literature; for context only, no clinical claims)

• CFH is a soluble regulator of the alternative complement pathway. It accelerates decay of the C3 convertase (C3bBb) and serves as a cofactor for factor I–mediated proteolysis of C3b, thereby limiting complement activation on host surfaces.
• Domain architecture: composed of multiple short consensus repeat (SCR) domains that mediate interactions with C3b, polyanions (e.g., glycosaminoglycans), and sialic acid on host cells.
• Expression: primarily hepatic secretion into plasma; local expression reported in various tissues and cell types.
• Research implications: transient CFH knockdown using siRNA enables interrogation of complement regulation, opsonization dynamics, and downstream signaling in cellular models and conditioned media.

Note

• The above roles are general background. This product contains no stated functional annotations beyond targeting CFH. Use appropriate controls and orthogonal assays (e.g., rescue with siRNA‑resistant CFH) for mechanistic studies.

Buffer Applications

Applicability

• This product is an siRNA set; classical acid/base buffer formulation utility is limited. However, selection of reconstitution and storage buffers is critical for stability and activity.

General guidance (literature)

• Stock preparation: dissolve each siRNA in RNase‑free water or TE buffer (10 mM Tris‑HCl, pH 7.5–8.0; 0.1–1 mM EDTA). Typical stock concentrations: 10–100 µM per strand/duplex.
• Working dilution: prepare in serum‑free medium (e.g., Opti‑MEM) immediately before complexing with the transfection reagent; add to cells per reagent protocol.
• pH considerations: near‑neutral pH (7.0–8.0) preserves ribose integrity; avoid alkaline conditions that promote transesterification.
• Ionic strength: monovalent salts (Na+, K+) at moderate levels are generally tolerated; divalent cations can enhance nuclease activity and alter complexation—use cautiously.

Brief recipes (illustrative; not product‑specific)

• TE buffer (1×): 10 mM Tris‑HCl, 0.1 mM EDTA, pH 7.5–8.0; filter sterilize; prepare RNase‑free.
• RNase‑free water: nuclease‑free by filtration and autoclaving; store in aliquots; avoid repeated opening.

Green Alternatives

Relevance

• For siRNA workflows, the main environmental considerations concern buffer selection, plasticware use, and transfection reagents rather than substitution of organic solvents.

Greener practice suggestions (general, literature)

• Replace DEPC treatment with certified RNase‑free, autoclaved water to avoid handling toxic carbamates.
• Choose lower‑toxicity, biodegradable transfection reagents where performance allows; minimize reagent excess to reduce cytotoxic waste.
• Consolidate oligo aliquoting to reduce single‑use plastics; use polypropylene that can be routed to institutional recycling streams where available.
• Avoid chloroform/phenol RNA extraction in favor of column‑based kits when compatible with your downstream analysis.

Comparison (illustrative; not product‑specific)

• Traditional: DEPC‑treated water; phenol/chloroform extraction; high plastic consumables.
• Greener alternative: RNase‑free water by filtration/autoclave; silica‑membrane kits; planned aliquoting to reduce waste.

Note

• These practices do not alter the composition or performance of the siRNA itself but can reduce hazard and waste in typical gene‑silencing workflows.

Pharmaceutical Uses

Not applicable to this catalog item as sold

• This siRNA set is designated for research use only (per Product Data). No clinical or therapeutic applications are claimed or supported.

General formulation context (literature; non‑clinical)

• In research, siRNA is often formulated transiently with cationic lipids or polymers for cell culture delivery. These systems are not pharmaceutical drug products and are optimized for in vitro transfection efficiency and acceptable cytocompatibility.
• Key parameters include N/P ratio (amine to phosphate), particle size/charge, serum compatibility, and stability during the transfection window.

Note

• Do not use this product for diagnostics, therapeutic interventions, or any in vivo administration. For any regulated application, dedicated GMP‑grade materials and extensive safety/efficacy validation are required.

Physical Properties

Item-specific (from Product Data)

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• Other specifications (e.g., UV/OD, purity): Not specified for this item; refer to CoA/Spec Sheet.

Typical properties for siRNA oligonucleotides (literature, for context only)

• Physical state: supplied lyophilized or in aqueous RNase‑free buffer.
• Solubility: readily soluble in RNase‑free water or TE buffer (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0).
• UV characteristics: λmax ≈ 260 nm; concentration estimation via A260 (1 A260 ≈ 40 µg/mL for single‑stranded RNA; duplex factors vary by sequence and length).
• Duplex melting temperature (Tm): sequence‑dependent; typical siRNA duplex Tm often 60–80 °C in standard buffers, elevated by GC content and salt.
• Stability: stable when lyophilized at −20 °C; in solution, improved stability at −20 °C in TE buffer and with RNase‑free handling.

Important

• Do not treat any of the above as product specifications. For exact values (strand length, OD, nmol, modification content), refer to the product’s CoA/Spec Sheet.

Quality and Grades

Item-specific (from Product Data)

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

Context and expectations for siRNA quality (literature; not product‑specific)

• Typical QC elements: MALDI‑TOF/ESI‑MS for mass confirmation; analytical HPLC or UPLC for purity profile; UV/OD for yield; strand stoichiometry and annealing confirmation.
• Purity options: desalted, cartridge‑purified, HPLC‑purified, or PAGE‑purified. For cell‑based knockdown, HPLC or PAGE purification is commonly selected to reduce n‑1 species and truncated products.
• Stabilizers/modifications: 2′‑O‑Me/2′‑F, phosphorothioate linkages, or terminal capping may be included to improve nuclease resistance and in‑cell longevity—no such details are provided for this item.
• Endotoxin and bioburden: some research workflows require low endotoxin oligos; acceptance criteria vary by lab SOP. Confirm via CoA if critical.

How to use this information

• If your application is sensitive (primary cells, low‑dose transfection), request the CoA/Spec Sheet to confirm: purification method, residual salts/solvents, OD units/nmol, and mass spectrometric identity.

Reaction and Applications

Focus for this product type

• As an siRNA set targeting human CFH, the primary application is sequence‑specific post‑transcriptional gene silencing in mammalian cells.

Mechanistic overview (literature)

• Pathway: duplex siRNA is loaded into the RNA‑induced silencing complex (RISC); the passenger strand is discarded; the guide strand directs Argonaute‑mediated cleavage or translational repression of complementary CFH mRNA.
• Design rationale: pre‑designed sets typically include multiple siRNA sequences to increase the chance of potent knockdown and enable pooling to mitigate off‑target effects—specific sequences are not provided for this item.

Use cases (research; non‑clinical)

• Validate CFH function in complement pathway studies, innate immunity models, or hepatic expression systems.
• Phenocopy CRISPR knockouts transiently to assess acute loss‑of‑function without genomic edits.
• Build dose–response curves for CFH expression versus phenotype; combine with rescue constructs for specificity control.

Practical tips (general)

• Use RNase‑free technique; thaw on ice; centrifuge briefly before opening.
• Start with 5–50 nM final siRNA per well (mammalian cells), optimize by cell line and reagent.
• Include controls: non‑targeting siRNA, positive knockdown control, and mock transfection.
• Assess knockdown at 24–72 h by qRT‑PCR and at 48–96 h by immunoblotting, as appropriate.

Reaction Conditions

Interpretation

• “Reaction conditions” for this product translate to transfection and knockdown assay conditions rather than chemical reaction parameters.

General experimental guidance (literature; optimize per system)

• Cell density: transfect at 40–70% confluence for adherent cell lines to balance uptake and viability.
• Dosing: begin at 5–25 nM final siRNA for standard lipofection; adjust 1–50 nM based on cell line sensitivity and reagent recommendations.
• Complexation: dilute siRNA and transfection reagent separately in serum‑free medium (e.g., Opti‑MEM), incubate 5–20 min to form complexes, then add to cells dropwise.
• Medium: many protocols permit serum during transfection; verify compatibility. Change to complete medium after 4–24 h if cytotoxicity is observed.
• Timing: assess mRNA knockdown at 24–48 h by qRT‑PCR; assess protein reduction at 48–96 h by immunoblot or ELISA depending on CFH secretion kinetics.
• Replicates/controls: include non‑targeting control, positive control siRNA, and mock. Consider pooled vs. individual duplexes to minimize off‑target effects.

Important

• These are literature‑based starting points. Follow your transfection reagent’s datasheet and adapt to your cell model.

Safety and Handling

Item-specific (from Product Data)

• GHS classification, signal word, H‑statements, pictograms: Not specified for this item; refer to SDS.
• Storage conditions: Store at −20 °C.
• Shipping: Shipped in an ice chest with ice pads.

General safety guidance (literature; defer to SDS for authoritative instructions)

• Hazard profile: synthetic siRNA oligonucleotides are generally considered low hazard; handle as laboratory chemicals. Avoid inhalation of dust/aerosols and contact with skin/eyes.
• PPE: laboratory coat, nitrile gloves, safety glasses. Change gloves frequently to avoid RNase contamination.
• Handling practices: work in a clean, RNase‑free area. Use certified RNase‑free tubes/tips; avoid autoclaved DEPC‑treated plastics that can retain residues.
• Incompatibilities: avoid RNases (ubiquitous enzymes) and strong oxidants; do not mix with microbial or biological samples without RNase control.
• First aid (overview): in case of contact, rinse skin/eyes with water for several minutes; if inhaled, move to fresh air; if ingested, rinse mouth and seek medical advice per SDS.
• Waste: dispose according to institutional guidelines for non‑hazardous, nucleic‑acid‑containing laboratory waste unless local rules specify otherwise.

Note

• Always consult the product‑specific SDS for definitive hazard and response measures.

Solvent Selection

Applicability to this product

• This item is an siRNA set; conventional organic “solvent selection” is not typically relevant. Reconstitution and handling in aqueous, RNase‑free media are the key considerations.

Practical guidance (literature)

• Primary diluents: RNase‑free water or TE buffer (10 mM Tris‑HCl, pH 7.5–8.0; 0.1–1 mM EDTA). TE provides modest stabilization against nuclease‑mediated degradation and metal‑catalyzed hydrolysis.
• Avoid: DEPC‑treated solutions containing residual DEPC/ethanol; bacterial media; buffers with divalent cations (e.g., Mg2+, Ca2+) unless explicitly required for downstream assays, as they can affect stability and transfection.
• Working solutions: prepare in sterile, nuclease‑free PBS or Opti‑MEM immediately prior to transfection as dictated by the transfection reagent protocol; minimize freeze–thaw.
• Co‑solvents: DMSO is occasionally used at trace levels to aid delivery in specialized systems, but many transfection reagents are incompatible with organic cosolvents—follow reagent vendor guidance.

Comparison (general)

• RNase‑free water: maximal compatibility; least buffering capacity; best for short‑term stocks.
• TE buffer: improved stability for frozen stocks; EDTA may be undesirable in cation‑dependent assays.
• PBS: isotonic for cell handling; phosphate can interact with some cationic lipids—verify with your transfection protocol.

Storage and Reconstitution

Item-specific (from Product Data)

• Storage: Store at −20 °C.
• Shipping: Ice chest with ice pads.
• Additional storage specifications (e.g., protection from light, number of freeze–thaw cycles, stabilizers): Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature; not product‑specific)

• Upon receipt: if lyophilized, briefly centrifuge tubes before opening to collect material at the bottom; allow to equilibrate to room temperature in a desiccator to minimize moisture condensation.
• Reconstitution: dissolve in RNase‑free water or TE buffer to 10–100 µM. Vortex gently and incubate on ice for 5–10 min to ensure full dissolution.
• Aliquoting: prepare single‑use aliquots to avoid repeated freeze–thaw. Label with concentration, buffer, and date.
• Storage of solutions: store aliquots at −20 °C (short‑ to mid‑term) or −80 °C (long‑term). Avoid more than 3–5 freeze–thaw cycles.
• Handling: maintain RNase‑free technique; use low‑bind tubes and filter tips. Thaw on ice; mix by gentle flicking or brief low‑speed spin.

Note

• For any item‑specific recommendations (e.g., annealed duplex vs. single strands, presence of carrier, or special stabilizers), consult the CoA/Spec Sheet.

Structure and Identity

Item-specific (from Product Data)

• Product name: CFH Human Pre-designed siRNA Set A (SKU: C1461378)
• Intended target: Human CFH gene (Complement factor H)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• CAS, CID, InChIKey, SMILES: Not specified for this item; refer to CoA/Spec Sheet.

General description (literature)

• siRNA constructs are typically double‑stranded RNA oligonucleotides (≈19–21 bp duplex) with 2‑nt 3′ overhangs (e.g., dTdT), designed to guide RISC to complementary mRNA for sequence‑specific silencing.
• Structural features: ribose sugar backbone (2′‑OH), phosphate diester linkages; may include optional chemical modifications (e.g., 2′‑O‑Me, phosphorothioates) to enhance stability—none are specified for this item.
• 2D depiction in words: two antiparallel RNA strands forming an A‑form helical duplex, 5′‑phosphate/3′‑hydroxyl termini (unless modified), with short 3′ overhangs; one strand designated “guide,” the other “passenger.”

Notes

• Sequence, length, modification pattern, and exact composition for this set are not provided in the Product Data. Consult the Certificate of Analysis (CoA) for sequence-level identity and QC details.

Synthetic Utility

Not typically applicable

• As an siRNA reagent, this product is not used as a chemical building block or reagent in classical organic synthesis.

Context (literature)

• Oligonucleotides are end‑products of solid‑phase synthesis and serve as functional biological tools (gene silencing) rather than synthetic intermediates. Any chemical transformations (e.g., conjugations, labeling) would be performed on the oligo itself using established bioconjugation chemistries (e.g., NHS ester to amine, maleimide to thiol), but no such features are specified for this item.

Target Specificity

Item-specific (from Product Data)

• Target gene: CFH (Complement factor H)
• Species: Human
• Additional details (sequences, exon targeting, validated off‑targets, knockdown efficiency, clone IDs): Not specified for this item; refer to CoA/Spec Sheet.

Notes

• When reporting results, document the exact sequences, lot numbers, and any pooling strategy once obtained from the CoA.